DrugPatentWatch Database Preview
CAMBIA Drug Profile
Email this page to a colleague
» See Plans and PricingWhen do Cambia patents expire, and when can generic versions of Cambia launch?
Cambia is a drug marketed by Assertio and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has thirty-two patent family members in twenty-three countries.
The generic ingredient in CAMBIA is diclofenac potassium. There are forty-seven drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the diclofenac potassium profile page.
US ANDA Litigation and Generic Entry Outlook for Cambia
A generic version of CAMBIA was approved as diclofenac potassium by TEVA on August 6th, 1998.
Summary for CAMBIA
| International Patents: | 32 |
| US Patents: | 4 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 45 |
| Clinical Trials: | 3 |
| Patent Applications: | 2,298 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CAMBIA |
| Drug Sales Revenues: | Drug sales revenues for CAMBIA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CAMBIA |
| DailyMed Link: | CAMBIA at DailyMed |
Recent Clinical Trials for CAMBIA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Scripps Health | Phase 4 |
| Depomed | Phase 4 |
| Mayo Clinic | Phase 2/Phase 3 |
Recent Litigation for CAMBIA
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| NAUTILUS NEUROSCIENCES, INC. v. WOCKHARDT USA LLC | 2012-02-27 |
| NAUTILUS NEUROSCIENCES, INC. v. EDICT PHARMACEUTICALS PVT. LTD. | 2011-07-20 |
| NAUTILUS NEUROSCIENCES, INC. v. WOCKHARDT USA LLC |
Pharmacology for CAMBIA
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
| Physiological Effect | Decreased Prostaglandin Production |
Synonyms for CAMBIA
| 15307-81-0 |
| 2-((2,6-dichlorophenyl)amino)benzeneacetic acid, monopotassium salt |
| AB0013318 |
| AC-18735 |
| AKOS015889752 |
| AKOS015994733 |
| Benzeneacetic acid, 2-((2,6-dichlorophenyl)amino)-, monopotassium salt |
| C14H10Cl2KNO2 |
| C14H10Cl2NO2.K |
| Cambia (TN) |
| Cataflam |
| Cataflam (TN) |
| CGP 45840B |
| CGP-45840B |
| CHEBI:4508 |
| CHEMBL1200804 |
| D00903 |
| DB-043176 |
| Diclofenac potassium |
| Diclofenac potassium (USAN) |
| Diclofenac potassium [USAN:USP] |
| Diclofenac potassium [USAN] |
| Diclofenac potassium salt |
| diclofenac-potassium |
| DTXSID30165212 |
| FT-0603076 |
| H866 |
| HMS3656D18 |
| KS-5037 |
| KXZOIWWTXOCYKR-UHFFFAOYSA-M |
| L4D5UA6CB4 |
| LS-173441 |
| Potassium (o-(2,6-dichloroanilino)phenyl)acetate |
| Potassium [2-(2,6-dichloroanilino)phenyl]acetate |
| potassium {2-[(2,6-dichlorophenyl)amino]phenyl}acetate |
| potassium 2-(2-((2,6-dichlorophenyl)amino)phenyl)acetate |
| potassium 2-(2-(2,6-dichlorophenylamino)phenyl)acetate |
| potassium;2-[2-(2,6-dichloroanilino)phenyl]acetate |
| PubChem5895 |
| Q27106401 |
| s3062 |
| SC-01315 |
| SCHEMBL40784 |
| SW196404-4 |
| UNII-L4D5UA6CB4 |
| Voltfast |
| Zipsor |
| Zipsor (TN) |
Paragraph IV (Patent) Challenges for CAMBIA
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| CAMBIA | FOR SOLUTION;ORAL | diclofenac potassium | 022165 | 2011-01-24 |
US Patents and Regulatory Information for CAMBIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | AB | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CAMBIA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | Start Trial | Start Trial |
| Assertio | CAMBIA | diclofenac potassium | FOR SOLUTION;ORAL | 022165-001 | Jun 17, 2009 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CAMBIA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Ecuador | SP077989 | Start Trial |
| Denmark | 0906092 | Start Trial |
| Poland | 1890680 | Start Trial |
| European Patent Office | 2705837 | Start Trial |
| Hong Kong | 1213814 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
